Sakurasaku Plus
7097
Timee
215A
Wintest
6721
Heartseed
219A
Raksul
4384
JP Stock MarketDetailed Quotes
4519 Chugai Pharmaceutical
- 6594.0
- -176.0-2.60%
20min DelayNot Open Dec 13 15:30 JST
11.07TMarket Cap33.34P/E (Static)
6772.0High6588.0Low2.67MVolume6712.0Open6770.0Pre Close17.76BTurnover7869.052wk High0.42%Turnover Ratio1.68BShares4572.052wk Low235.15EPS TTM4.22TFloat Cap7869.0Historical High33.34P/E (Static)639.51MShs Float283.3Historical Low197.8EPS LYR2.72%Amplitude81.00Dividend TTM6.19P/B100Lot Size1.23%Div YieldTTM
Chugai Pharmaceutical Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 22.40%315.68B | 18.13%315.91B | -24.11%236.95B | -11.78%1.11T | -37.56%273.81B | 14.48%257.9B | 13.50%267.42B | -13.35%312.24B | 26.00%1.26T | 36.07%438.5B |
| Cost of revenue | 7.62%84.22B | -4.06%87.94B | -51.79%72.95B | -13.22%413.31B | -56.76%92.06B | 13.26%78.26B | 14.83%91.66B | 32.25%151.33B | 40.84%476.25B | 92.58%212.91B |
| Gross profit | 28.85%231.46B | 29.71%227.97B | 1.92%164B | -10.90%698.06B | -19.43%181.75B | 15.02%179.64B | 12.82%175.76B | -34.57%160.91B | 18.42%783.48B | 6.55%225.59B |
| Operating expense | -2.61%71.05B | 10.31%69.65B | 2.41%64.13B | 3.49%258.89B | -20.94%60.18B | 23.02%72.96B | 13.06%63.14B | 6.30%62.62B | 4.36%250.17B | 4.77%76.11B |
| Selling and administrative expenses | 0.86%27.78B | -17.88%27.32B | 7.47%22.59B | 12.05%112.58B | 0.02%30.76B | 15.82%27.54B | 43.65%33.26B | -7.77%21.02B | -1.89%100.48B | -11.73%30.75B |
| -Selling and marketing expense | 0.86%27.78B | -17.88%27.32B | 7.47%22.59B | 12.05%112.58B | 0.02%30.76B | 15.82%27.54B | 43.65%33.26B | -7.77%21.02B | 31.18%100.48B | 26.32%30.75B |
| Research and development costs | -1.44%44.92B | -3.66%42.94B | -3.53%41.36B | 16.87%174.87B | -7.46%41.86B | 24.15%45.57B | 31.79%44.57B | 26.58%42.87B | 8.98%149.63B | 19.64%45.23B |
| Other operating expenses | -928.13%-1.65B | 95.90%-603M | 114.59%185M | -44,726.56%-28.56B | -9,817.97%-12.44B | 86.53%-160M | -1,203.82%-14.69B | -156.36%-1.27B | --64M | --128M |
| Operating profit | 50.35%160.41B | 40.59%158.32B | 1.60%99.87B | -17.65%439.17B | -18.66%121.58B | 10.11%106.69B | 12.68%112.62B | -47.44%98.3B | 26.41%533.31B | 7.49%149.47B |
| Net non-operating interest income (expenses) | -299.24%-1.57B | -65.22%480M | -98.90%15M | 51,733.33%4.65B | 311.79%1.11B | 142.48%788M | 78.53%1.38B | -14.63%1.37B | -132.14%-9M | 40.30%-526M |
| Non-operating interest income | ---490M | -65.44%480M | -98.90%15M | ---- | ---- | ---- | 76.27%1.39B | -15.24%1.37B | ---- | ---- |
| Non-operating interest expense | ---- | ---- | ---- | -55.74%27M | -50.00%8M | -53.33%7M | -40.00%9M | -85.71%2M | 27.08%61M | 33.33%16M |
| Total other finance cost | ---- | ---- | ---- | -8,888.46%-4.67B | -320.00%-1.12B | -143.21%-795M | ---- | ---- | 31.58%-52M | -41.31%510M |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | ||||||||||
| Other non-operating income (expenses) | 15.98%-2.13B | 3.09%267M | ||||||||
| Income before tax | 47.79%158.84B | 39.31%158.8B | 0.23%99.89B | -16.44%443.82B | -17.78%122.69B | 13.09%107.48B | 13.19%113.99B | -46.48%99.66B | 26.65%531.17B | 7.78%149.22B |
| Income tax | 65.00%49.34B | 52.40%46.94B | -2.57%25.49B | -24.49%118.35B | -32.64%31.48B | 9.80%29.9B | 8.70%30.8B | -51.94%26.16B | 34.67%156.74B | 18.03%46.74B |
| Net income | 41.15%109.5B | 34.46%111.86B | 1.23%74.4B | -13.08%325.47B | -11.00%91.21B | 14.42%77.57B | 14.94%83.19B | -44.22%73.5B | 23.58%374.43B | 3.68%102.48B |
| Net income continuous operations | 41.15%109.5B | 34.46%111.86B | 1.23%74.4B | -13.08%325.47B | -11.00%91.21B | 14.42%77.57B | 14.94%83.19B | -44.22%73.5B | 23.58%374.43B | 3.68%102.48B |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 41.15%109.5B | 34.46%111.86B | 1.23%74.4B | -13.08%325.47B | -11.00%91.21B | 14.42%77.57B | 14.94%83.19B | -44.22%73.5B | 23.58%374.43B | 3.68%102.48B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 41.15%109.5B | 34.46%111.86B | 1.23%74.4B | -13.08%325.47B | -11.00%91.21B | 14.42%77.57B | 14.94%83.19B | -44.22%73.5B | 23.58%374.43B | 3.68%102.48B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 41.15%66.55 | 34.43%67.98 | 1.21%45.22 | -13.10%197.83 | -11.01%55.43 | 14.41%47.15 | 14.93%50.57 | -44.25%44.68 | 23.52%227.64 | 3.61%62.29 |
| Diluted earnings per share | 41.13%66.53 | 34.43%67.97 | 1.21%45.21 | -13.08%197.8 | -11.00%55.43 | 14.42%47.14 | 14.94%50.56 | -44.23%44.67 | 23.57%227.57 | 3.66%62.28 |
| Dividend per share | 0 | 2.50%41 | 0 | 2.56%80 | 0.00%40 | 0 | 5.26%40 | 0 | 2.63%78 | -13.04%40 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |